Annals of Hematology

, Volume 93, Issue 1, pp 99–105 | Cite as

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

  • Silvia Park
  • Su Jin Lee
  • Chul Won Jung
  • Jun Ho Jang
  • Seok Jin Kim
  • Won Seog Kim
  • Kihyun Kim
Original Article


Multiple myeloma remains incurable despite the use of novel agents. Dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) is one of the salvage options, but there has been a lack of data on salvage DCEP in patients with previous exposure to novel agents. A total of 59 patients who received DCEP chemotherapy between 2006 and 2013 were retrospectively reviewed. The patients who had been exposed to thalidomide, lenalidomide, or bortezomib prior to DCEP were eligible. The median age at DCEP was 58 years, and DCEP treatment was initiated at a median of 34.9 months from diagnosis. Before DCEP, patients exposed to a median of three lines of treatment and 55 patients (81.4 %) had undergone autohematopoietic stem cell transplantation. Among 51 patients with data available for response assessment, response rate was 45.1 % (1 with complete response, 1 with very good partial response, and 21 with partial response); an additional 18 patients benefited from this regimen (8 with minor response and 10 stable diseases). Grade ≥3 neutropenia was observed in 91.5 %. Treatment-related mortality (TRM) was reported in eight patients (14.8 %), and seven of eight deaths were related to febrile neutropenia. Median overall survival and progression-free survival were estimated at 8.0 and 3.7 months, respectively. DCEP is an effective salvage treatment options for relapsed or refractory multiple myeloma in the setting of previous use of novel agents. However, hematologic toxicities and TRM were substantial, and concurrent use of prophylactic granulocyte-colony stimulating factor is warranted.


Multiple myeloma Novel agents Salvage regimen 



This study was supported by Samsung Medical Center grant CRS 1100331

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121:884–892. doi: 10.1182/blood-2012-05-432203 PubMedCrossRefGoogle Scholar
  2. 2.
    Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2475–2482. doi: 10.1200/JCO.2011.37.4918 PubMedCrossRefGoogle Scholar
  3. 3.
    Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679–686. doi: 10.1182/blood-2010-02-268862 PubMedCrossRefGoogle Scholar
  4. 4.
    Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494PubMedCrossRefGoogle Scholar
  5. 5.
    Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89–96PubMedCrossRefGoogle Scholar
  6. 6.
    Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114:772–778. doi: 10.1182/blood-2008-12-196238 PubMedCrossRefGoogle Scholar
  7. 7.
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498. doi: 10.1056/NEJMoa043445 PubMedCrossRefGoogle Scholar
  8. 8.
    Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A (2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141:814–819. doi: 10.1111/j.1365-2141.2008.07147.x PubMedCrossRefGoogle Scholar
  9. 9.
    Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA (2008) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22:2247–2256. doi: 10.1038/leu.2008.235 PubMedCrossRefGoogle Scholar
  10. 10.
    Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omede P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foa R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 25:4459–4465. doi: 10.1200/JCO.2007.12.3463 PubMedCrossRefGoogle Scholar
  11. 11.
    Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B (2008) VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22:1419–1427. doi: 10.1038/leu.2008.99 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Lonial S (2010) Relapsed multiple myeloma. Hematol Am Soc Hematol Educ Program 2010:303–309. doi: 10.1182/asheducation-2010.1.303 CrossRefGoogle Scholar
  13. 13.
    Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119:5661–5670. doi: 10.1182/blood-2012-03-414359 PubMedCrossRefGoogle Scholar
  14. 14.
    Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:4906–4915. doi: 10.1182/blood-2010-04-276626 PubMedCrossRefGoogle Scholar
  15. 15.
    Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC (2012) Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 120:3958–3967. doi: 10.1182/blood-2012-01-401794 PubMedCrossRefGoogle Scholar
  16. 16.
    Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA (2011) Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11:254–284PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Siegel D, Dimopoulos MA, Yoon SS et al (2011) Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood. ASH Annual Meeting Abstracts 118:480Google Scholar
  18. 18.
    Raje N HP, Vogl DT et al (2012) Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. Blood (ASH Annual Meeting Abstracts) 120:4061Google Scholar
  19. 19.
    Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121:1961–1967. doi: 10.1182/blood-2012-08-450742 PubMedCrossRefGoogle Scholar
  20. 20.
    Jakubowiak A (2012) Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol 49(Suppl 1):S16–S32. doi: 10.1053/j.seminhematol.2012.05.003 PubMedCrossRefGoogle Scholar
  21. 21.
    Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008–5014. doi: 10.1200/JCO.2009.23.6802 PubMedCrossRefGoogle Scholar
  22. 22.
    Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumano M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savare M, Vismara A, Morra E (2001) DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 28:835–839. doi: 10.1038/sj.bmt.1703240 PubMedCrossRefGoogle Scholar
  23. 23.
    Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A (2008) DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 48:857–860. doi: 10.1111/j.1537-2995.2007.01621.x PubMedCrossRefGoogle Scholar
  24. 24.
    Novella E, Madeo D, Albiero E, Roberti S, Castaman G, Elice F, Rodeghiero F (2004) Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma. Leuk Lymphoma 45:1497–1499. doi: 10.1080/10428190410001663644 PubMedCrossRefGoogle Scholar
  25. 25.
    Munshi N DK, Jagannath S et al (1996) Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT) [abstract 586a] Blood 88Google Scholar
  26. 26.
    Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C (2007) Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 12:41–44PubMedGoogle Scholar
  27. 27.
    NCCN (2013) Multiple myleoma. NCCN guidelines version 2Google Scholar
  28. 28.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 20:1467–1473. doi: 10.1038/sj.leu.2404284 CrossRefGoogle Scholar
  29. 29.
    Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 23:3–9. doi: 10.1038/leu.2008.291 CrossRefGoogle Scholar
  30. 30.
    Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79:867–874. doi: 10.1016/S0025-6196(11)62152-6 PubMedCrossRefGoogle Scholar
  31. 31.
    Dimopoulos MA, San-Miguel JF, Anderson KC (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 86:1–15. doi: 10.1111/j.1600-0609.2010.01542.x PubMedCrossRefGoogle Scholar
  32. 32.
    Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ (2010) Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 89:475–482. doi: 10.1007/s00277-009-0856-x PubMedCrossRefGoogle Scholar
  33. 33.
    Harousseau JL, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v155–v157. doi: 10.1093/annonc/mdq178 PubMedCrossRefGoogle Scholar
  34. 34.
    Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI (2013) D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 161:802–810. doi: 10.1111/bjh.12325 PubMedCrossRefGoogle Scholar
  35. 35.
    Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732–2739. doi: 10.1200/JCO.2003.01.055 PubMedCrossRefGoogle Scholar
  36. 36.
    Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE, Saso RM, Dines S, Morgan GJ (2008) Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 81:432–436. doi: 10.1111/j.1600-0609.2008.01131.x PubMedCrossRefGoogle Scholar
  37. 37.
    Oriol A (2011) Multiple myeloma with extramedullary disease. Adv Ther 28(Suppl 7):1–6. doi: 10.1007/s12325-011-0079-0 PubMedCrossRefGoogle Scholar
  38. 38.
    Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761–1767. doi: 10.3324/haematol.2012.065698 PubMedCrossRefGoogle Scholar
  39. 39.
    Calvo-Villas JM, Alegre A, Calle C, Hernandez MT, Garcia-Sanchez R, Ramirez G (2011) Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 87:281–284. doi: 10.1111/j.1600-0609.2011.01644.x PubMedCrossRefGoogle Scholar
  40. 40.
    Krauth MT, Bankier A, Valent P, Kalhs P, Drach J (2005) Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res 29:1473–1477. doi: 10.1016/j.leukres.2005.05.003 PubMedCrossRefGoogle Scholar
  41. 41.
    Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E (2004) Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89:832–836PubMedGoogle Scholar
  42. 42.
    Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J, Cobo F, Villela L, Rafel M, Nomdedeu B, Montserrat E (2001) Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 113:422–424PubMedCrossRefGoogle Scholar
  43. 43.
    Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I (2001) Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 42:683–687. doi: 10.3109/10428190109099330 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Silvia Park
    • 1
  • Su Jin Lee
    • 1
  • Chul Won Jung
    • 1
  • Jun Ho Jang
    • 1
  • Seok Jin Kim
    • 1
  • Won Seog Kim
    • 1
  • Kihyun Kim
    • 1
  1. 1.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations